The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The sensitization of immune checkpoint inhibitors with subsequent chemotherapy in R/R HL
Jan Maciej Zaucha, MD, Medical University of Gdansk, Gdańsk, Poland, discusses the sensitization of immune checkpoint inhibitors with subsequent chemotherapy in relapsed/refractory (R/R) Hodgkin lymphoma (HL). He mentions a study showing that the addition of salvage chemotherapy after nivolumab treatment improved response rates. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosures: Takeda.
